Johnson & Johnson entered into a definitive agreement to acquire Ambrx Biopharma Inc. for $1.8 billion.
Centerview Partners LLC is acting as lead financial advisor and fairness opinion provider and Cantor Fitzgerald & Co. is acting as financial advisor to Ambrx; Ray Bogenrief, Timothy F. Nelson, Maria Raptis, Graham Robinson Jack P. Rossman, Resa K. Schlossberg, Moshe Spinowitz and Chadé Severin of Skadden, Arps, Slate, Meagher & Flom LLP are serving as legal counsels. Robert I. Townsend, III, Sanjay Murti and Jin-Kyu Baek of Cravath, Swaine & Moore LLP are legal advisors to Johnson & Johnson. Innisfree M&A Incorporated acted as proxy solicitor to Ambrx Biopharma and Innisfree will receive approximately $40,000 for the service. Equiniti Trust Company acted as transfer agent to Ambrx Biopharma. Ambrx has agreed to pay Centerview an aggregate fee of approximately $26.9 million, $1 million of which was payable upon the rendering of Centerview?s opinion and the remainder of which is payable contingent upon consummation of the Merger.